{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:08Z","timestamp":1787027768586,"version":"build-2736575974"},"reference-count":54,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>T-cell lymphomas are a heterogeneous group of lymphoid neoplasms with a variable prognosis. They can be further divided into cutaneous T-cell lymphomas and peripheral T-cell lymphomas. Treatment options are relatively limited for patients with relapsed or refractory disease. Janus kinase (JAK) inhibitors have emerged as promising new drugs for these lymphomas, as increasing evidence supports the JAK and signal transducer and activator of transcription (STAT) pathway as a potential target. The objective of this review is to summarize the current evidence supporting the use of JAK inhibitors in the treatment of T-cell lymphomas and highlight areas for future research. Although many JAK inhibitors have been developed for the treatment of autoimmune conditions, only a subset of these have been tested in T-cell lymphomas and reported in the literature. These include abrocitinib, cerdulatinib, golidocitinib, ruxolitinib, tofacitinib, and upadacitinib. Other drugs are currently being tested in clinicals trials, including pacritinib and ivarmacitinib, but results are not yet available. Most of the published data are for ruxolitinib, which was found to have a clinical benefit rate of up to 53% in patients with PTCL with activating JAK and\/or STAT mutations. Response durations are limited, which may be overcome through combination therapies in the future. JAK inhibitors are associated with multiple adverse effects, including cytopenias and infections, and long-term safety data are lacking for newer agents. Future studies will need to clarify long-term safety and efficacy through well-designed clinical trials involving larger groups of patients.<\/jats:p>","DOI":"10.3390\/cancers18050799","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:18:45Z","timestamp":1772554725000},"page":"799","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7239-0335","authenticated-orcid":false,"given":"Gardenia","family":"Taza","sequence":"first","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-3852","authenticated-orcid":false,"given":"John L.","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN Guidelines Insights: Non-Hodgkin\u2019s Lymphomas, Version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3324\/haematol.2022.281226","article-title":"Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome","volume":"108","author":"Veloza","year":"2023","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells","volume":"6","author":"Kucuk","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.18098","article-title":"Advanced-stage mycosis fungoides: Role of the signal transducer and activator of transcription 3, nuclear factor-\u03baB and nuclear factor of activated T cells pathways","volume":"182","author":"Cereceda","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.14984","article-title":"Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma","volume":"183","author":"Manso","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-018-0138-8","article-title":"Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma","volume":"8","author":"Han","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic Mechanisms of JAK Inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Constantinescu, S.N., Vainchenker, W., and Pecquet, C. (2026). Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms. Blood.","DOI":"10.1182\/blood.2025028645"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kashyap, A., Dai, J., and Ni, X. (2025). Therapeutic Targeting of the Janus Kinase\/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma. Cancers, 17.","DOI":"10.3390\/cancers17040568"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute Graft-versus-Host Disease\u2014Biologic Process, Prevention, and Therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood.2023022735","article-title":"Chronic graft-versus-host disease: Unresolved complication or ancient history?","volume":"144","author":"Pidala","year":"2024","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1080\/10428194.2022.2118537","article-title":"Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma","volume":"63","author":"Watson","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jha2.143","article-title":"Ruxolitinib is effective in the treatment of a patient with refractory T-ALL","volume":"2","author":"Jaramillo","year":"2020","journal-title":"EJHaem"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70047","DOI":"10.1002\/jha2.70047","article-title":"Treatment of an Indolent T-Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 with Jakafi (Ruxolitinib) with Significant Clinical Improvements","volume":"6","author":"Cao","year":"2025","journal-title":"EJHaem"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/1346-8138.17747","article-title":"Oral and Topical Janus Kinase Inhibitors in Patients with Cutaneous T-Cell Lymphoma: A Real-World Single-Center Experience","volume":"52","author":"Liao","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/bloodadvances.2020001497","article-title":"Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis","volume":"4","author":"Fusaro","year":"2020","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/09546634.2019.1673877","article-title":"Off-label studies on tofacitinib in dermatology: A review","volume":"32","author":"Tegtmeyer","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"76793","DOI":"10.18632\/oncotarget.12529","article-title":"Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells","volume":"7","author":"Ando","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdcr.2024.11.007","article-title":"Treatment of Sezary syndrome with combination romidepsin and tofacitinib: A case report","volume":"55","author":"Suhl","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1080\/10428194.2019.1594220","article-title":"Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1\/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation","volume":"60","author":"Margolskee","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.annonc.2023.08.013","article-title":"Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas","volume":"34","author":"Song","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): A single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_32","first-page":"1681","article-title":"Anti-adult T-cell leukemia\/lymphoma activity of cerdulatinib, a dual SYK\/JAK kinase inhibitor","volume":"53","author":"Ishikawa","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1080\/10428194.2025.2455489","article-title":"Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase\/janus kinase inhibitor, in relapsed\/refractory peripheral T-cell lymphoma","volume":"66","author":"Horwitz","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jdcr.2022.10.010","article-title":"A case of erythrodermic mycosis fungoides responding to upadacitinib","volume":"30","author":"Castillo","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_36","first-page":"450","article-title":"Severely pruritic mycosis fungoides successfully treated with upadacitinib","volume":"22","author":"Kook","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/ijd.17469","article-title":"A case of recalcitrant folliculotropic mycosis fungoides successfully treated by abrocitinib","volume":"64","author":"Liu","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_38","unstructured":"Incyte Corporation (2026, January 05). Ruxolitinib Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202192lbl.pdf."},{"key":"ref_39","unstructured":"Pfizer Corportation (2026, January 05). Tofacitinib Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf."},{"key":"ref_40","unstructured":"AbbVie Corportation (2026, January 05). Upadacitinib Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s003lbl.pdf."},{"key":"ref_41","unstructured":"Pfizer Corportation (2026, January 05). Abrocitinib Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213871s001lbl.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaad.2021.09.051","article-title":"Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration\u2019s September 1, 2021, data safety communication","volume":"86","author":"Murphrey","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"The Lancet Rheumatology (2024). JAK inhibitors-Friend or Foe?. Lancet Rheumatol., 6, e129.","DOI":"10.1016\/S2665-9913(24)00033-X"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"pe32","DOI":"10.1111\/jdv.19408","article-title":"Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib","volume":"38","author":"Cohen","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000002219","article-title":"A Case of Tofacitinib-Induced Lymphomatoid Papulosis with Ocular Involvement","volume":"44","author":"Knapp","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1684\/ejd.2022.4238","article-title":"Lymphomatoid papulosis during upadaci-tinib treatment for rheumatoid arthritis","volume":"32","author":"Iinuma","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2050313X241231491","DOI":"10.1177\/2050313X241231491","article-title":"Cutaneous T-cell lymphoma in a JAK inhibitor patient: A case report","volume":"12","author":"Mo","year":"2024","journal-title":"SAGE Open Med Case Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1684\/ejd.2023.4554","article-title":"Acceleration of cutaneous T-cell lymphoma mistaken for atopic dermatitis following JAK inhibitor use","volume":"33","author":"Lamolet","year":"2023","journal-title":"Eur. J. Dermatol."},{"key":"ref_50","first-page":"91","article-title":"Cutaneous T-cell lymphomas initially diagnosed as inflammatory dermatoses and treated with biologics and small molecules","volume":"24","year":"2025","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2025.01.088","article-title":"Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center","volume":"92","author":"Liao","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1182\/bloodadvances.2023012531","article-title":"Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: Results from the Netherlands Cancer Registry","volume":"8","author":"Brink","year":"2024","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2024-206462","article-title":"Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vahabi, S.M., Bahramian, S., Esmaeili, F., Danaei, B., Kalantari, Y., Fazeli, P., Sadeghi, S., Hajizadeh, N., Assaf, C., and Etesami, I. (2024). JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature. Cancers, 16.","DOI":"10.3390\/cancers16050861"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/799\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:31:20Z","timestamp":1772775080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050799"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050799","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}